Ib Study of the Efficacy and Safety of IBI310 Combined With Sintilimab in Advanced Hepatocellular Carcinoma

  • STATUS
    Recruiting
  • participants needed
    47
  • sponsor
    Innovent Biologics (Suzhou) Co. Ltd.
Send
Updated on 16 February 2024
See if I qualify

Summary

An open-label, single-arm, Ib study of the efficacy and safety of IBI310 combined with sintilimab in patients with advanced hepatocellular carcinoma

Description

In this study, approximately 18 to 47 patients who have previously received sorafenib, lenvatinib, or oxaliplatin-containing chemotherapy . After determining the dose of IBI310, the study will enter the expansion phase

Details
Condition Advanced Hepatocellular Carcinoma
Age 18years - 75years
Treatment IBI308 200mg
Clinical Study IdentifierNCT04401813
SponsorInnovent Biologics (Suzhou) Co. Ltd.
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Locally advanced or metastatic hepatocellular carcinoma, confirmed by histology/cytology
Disease progression after surgery and / or local treatment
Previous standard systemic treatments for advanced hepatocellular carcinoma have failed or developed intolerable toxicity

Exclusion Criteria

Histology contains fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma and other components
Have a history of hepatic encephalopathy, or have a history of liver transplantation
Diffuse liver cancer
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.